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Abstract 
Physicians are constantly being exposed to new evidence that may effect how 
they practice medicine. While they read medical journals that contain peer-reviewed 
publications and attend scientific meetings at which results are presented, quite often they 
learn of new medical developments through the general consumer media. This paper 
summarizes the results of two case studies evaluating the impact of new clinical data and 
related media events on physician prescribing behavior within two different therapeutic 
classes: antipsychotics, used to treat psychosis, and female contraceptives. The analysis 
included a time-series analysis of total prescriptions (TRx) and market share(% ofTRx) 
in the timeframe pre- and post- publication oflandmark clinical data and surrounding 
media events. 
Results from these case studies suggest that the communication of landmark 
clinical data had a significant influence on physician prescribing behavior within both 
therapeutic classes. Although more rigorous statistical analysis would be required to 
definitively prove a correlation, in both case studies- antipsychotics and contraceptives-
physicians appear to be more influenced by media communication of new data than by 
the publication of the CATIE study results (antipsychotics) and the FDA's advisory on 
updated labeling for the contraceptive patch Ortho Evra (contraceptives), respectively. 
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Introduction 
The objective of this paper is to evaluate the impact of media events on physician 
prescribing behavior for two therapeutic categories: antipsychotics and contraceptives. In 
this analysis, the media events selected focused on the publication oflandmark clinical 
trial results (antipsychotics) and new safety information for a marketed contraceptive. 
There are several ways in which physicians are exposed to new evidence. They may read 
medical j oumals, attend scientific meetings at which results are presented, or hear about 
this information through the media. This analysis will aim to gauge changes in physician 
prescribing behavior over time in response to publicity surrounding major medical 
events, each covered widely in the media. 
Utilizing a proprietary prescription database, which captures nearly half of all 
prescription activity in the US, two time-series analyses were performed. The first 
analysis (Case Study 1) is conducted on the antipsychotic market to evaluate an effect on 
antipsychotics, which are primarily prescribed by psychiatrists. The second analysis 
(Case Study 2) examines the effect on contraceptive prescribing by ob/gyns. 
Case Study 1 - Antipsychotics 
Introduction 
Although the pharmaceutical industry has conducted a significant number of 
studies in the treatment of major psychiatric illnesses, the majority of these studies: have 
been designed to evaluate a single product, are short-term in duration (i.e., 8 to 12 
weeks), and may not reflect all schizophrenia patients due to study inclusion/ exclusion 
criteria. Understanding the need for long-term, objective comparative data in a broad 
population of schizophrenia patients, in January 2001, the National Institute of Mental 
Health (NIMH) initiated a study of a first-generation antipsychotic, perphenazine, vs. 
several newer second-generation antipsychotics. 1 At that time, the relative effectiveness 
of these second-generation atypical antipsychotics as compared with that of older 
antipsychotics was incompletely addressed, although newer agents were (and still are) 
used far more readily due to the more favorable side effect profile. 1 This stndy was one 
of four trials funded over a six year period by the mental-health division of the National 
Institutes of Health to produce reliable scientific data regarding the differences between 
drugs and treatment strategies for the major psychiatric illnesses.2 
The CATIE (Clinical Antipsychotic Trials in Intervention Effectiveness) 
Schizophrenia Study (Comparative Effectiveness of Antipsychotic Medications in 
Patients with Schizophrenia) was a comparator study of the newer atypical antipsychotics 
( olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), ziprasidone 
(Geodon)) with each other and with the first-generation antipsychotic perphenazine. Led 
by Jeffrey Lieberman of Columbia University and director ofthe New York State 
Psychiatric Institute, the stndy involved 1,493 schizophrenic patients at 57 US medical 
centers randomized to 18 months of treatment. 1 The specific aims of the stndy were I. to 
determine the long-term effectiveness and tolerability (all-cause treatment 
discontinuation) of the newer atypical antipsychotics, relative to each other, 2. to 
determine the long-term effectiveness and tolerability of the newer atypical 
antipsychotics relative to a conventional antipsychotic (perphenazine), 3. to determine, 
among patients who fail treatment with an initially assigned newer atypical antipsychotic 
due to lack of efficacy, the long-term effectiveness and tolerability of the other newer 
atypical antipsychotics, relative to clozapine, and 4. to determine, among patients who 
discontinue treatment with an initially assigned newer atypical antipsychotic due to 
treatment intolerance, the long-term effectiveness and tolerability of the other newer 
atypical antipsychotics, relative to ziprasidone.3 
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Published in the September 22, 2005 issue of the New England Journal of 
Medicine, results from theCA TIE study, published widely in the media, found that the 
newer, more expensive atypical antipsychotics are no more effective and no safer than an 
older, less expensive medication (perphenazine (Trilafon)) that many physicians no 
longer use. The most striking finding was that 74% of patients discontinued their 
assigned study medication, due to lack of efficacy and/or adverse side effects, and 
switched to another before 18 months (1061 of the 1432 patients who received at least 
one dose)1• According to Thomas Insel, director of NIMH: "The study has vital public 
health implications. It is the largest, longest and most comprehensive, independent trial 
ever done to examine existing therapies for this disease." 
Recognizing the importance of the CATIE study to physician treatment of 
schizophrenia, in this analysis the effect of the study findings on physician prescribing 
habits was evaluated. Because of the significant amount of negative publicity that 
surfaced during the course of the CATIE study in mid-2003 regarding weight gain 
associated with the second generation antipsychotics, particularly Zyprexa, concerns 
abounded that focusing solely on changes following publication of the CATIE study 
results would be incomplete. As a result, the analysis was broadened to look at the 
impact on prescribing over the entire five-year time frame so as to evaluate the effect of 
these Zyprexa-related media events on prescribing habits. 
Methods 
To investigate the impact of clinical findings during and following the CATIE 
study, the key media communications surrounding the study initiation, interim publicity, 
and results dissemination were identified, and, once complete, the impact of this 
information on use of antipsychotic therapies from January 2002 to December 2005 was 
evaluated. A time series analysis was set-up in order to gauge any effect. 
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Although the CATIE study was initiated in January 2001, January 2002 was 
chosen as a starting point for the analysis due to limitations in availability of retail 
prescription data. December 2005 was selected as the end date because it was not only 
the most recent month of data, but also captures the publicity surrounding publication of 
the final study results in September 2005. 
Retail pharmacy prescription data for the antipsychotic schizophrenia treatments 
Zyprexa (oral), Seroquel, Risperdal (oral), Geodon (oral), and perphenazine were 
obtained from Verispan, a joint venture between Quintiles and McKesson. The Verispan 
data captures more than 1.4 billion patient-centric prescriptions per year, nearly half of all 
prescription activity in the US, and is a proprietary service of Quintiles, Inc. 4 Total 
prescriptions (TRx) and market share(% ofTRx) was obtained from January 2002 
through December 2005. Risperdal Consta, Zyprexa Zydis, and the Geodon IM ~-
b 
injectable formulations of these drugs were not included in this prescription data as they ¥-
are not typically dispensed through retail pharmacy and thus, capture through the 
Verispan data is incomplete. However, this should not affect the analysis as an 
examination of the TRx for the non-oral formulations show that they are a small fraction 
of the overall TRx for these antipsychotics. 
To identifY media communications surrounding the study, an Internet search in 
Google from January 2001 to March 2006 using the following terms was conducted (see 
Attachment A): 
• Dr. Jeffrey Lieberman+ CATIE 
• Effectiveness of Antipsychotic Drugs in Patients 
Understanding the importance of communications regarding weight gain 
associated with Zyprexa use, a supplemental search was conducted using the terms 
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"weight gain"+ "Zyprexa" (see Attachment B). Articles or references to articles 
contained within the following formats were excluded: 
• Personal blogs (articles from "periodical type" blogs were included) 
• Listings of ongoing clinical trials (unless preliminary results were mentioned as a part 
of the listing) 
• Listings of the article and/or abstract itself 
• Listings of ongoing litigation 
• Speaking engagement announcements where the article is referenced 
• Articles not written in English 
Results 
Communication of Efficacy and Safety Data for Antipsychotics 
The analysis of media events identified seven major communications that could 
potentially influence physician-prescribing behavior: 
• Increased Prevalence of Diabetes Among Patients Receiving Antipsychotic Drugs, 
May 30,2003 
• Weight Gain is Potential Problem in Patients Switched from Risperidal to Zyprexa, 
October 16, 2003 
• Zyprexa Efficacy Questionable, November 25, 2003 
• Zyprexa Class Action Lawsuit Announced, Aprill9, 2004 
• The Next Phase in Psychiatry: Largest Ever Studies on Drugs for Depression, 
Schizophrenia Could Transform Treatment, July 27,2005 
• Study Shows Older, Cheaper Drug is Effective as Newer Antipsychotic Meds, 
September 2005 
• Study Finds Little Advantage In New Schizophrenia Drugs, September 20, 2005 
As can be seen from the list of communications above, outside of the press 
surrounding the CATIE study, the major data being published was related to the impact 
of antipsychotics on weight/diabetes. The evidence linking the atypical products, and in 
particular Zyprexa, to the metabolic side effect began in May 2003 with reports related to 
a significantly higher rate of diabetes among patients receiving antipsychotics. 5 In 
October 2003, Zyprexa was specifically and prominently targeted for its induction of 
significant increases in body mass index weight gain in patients taking it.6 Soon 
thereafter, media reports began appearing linking Zyprexa to other serious side effects 
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including altered lipid profile, hyperglycemia, pancreatitis, ketoacidosis, and diabetic 
coma. In November 2003, the results of a study sponsored by Eli Lilly & Co. revealed 
that its very own Zyprexa may not be a much more effective treatment than older and 
cheaper schizophrenic medications.7 Finally, in April2004, the filing ofthe first 
nationwide (US) Zyprexa class action lawsuit was announced against Eli Lilly & Co8 
Prescription Data 
Figure 1 presents total prescriptions (TRx) from January 2002 to December 2005, 
inclusive, for all antipsychotics (antipsychotic prescription data was not available for 
calendar year 2001 when the CATIE study began enrolhnent) graphed concurrently with 
the timing of the 7 key data communications outlined above. As can be seen in Figure 1, 
there has been a leveling off of prescriptions for antipsychotics in the early 2003 to late 
2005 timeframe, which suggests that much of the change in volume across agents 
observed during this timeframe is really a shift in prescribing behavior among products 
rather than an expansion in the market size. It is interesting to note that the plateau in · 
market growth occurred around the time that negative data was communicated on weight 
gain associated with atypical antipsychotics, and in particular, with Zyprexa, one of the 
leading products at the time. 
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Figure 2 presents total prescriptions (TRx) from January 2002 to December 2005, 
inclusive, for each individual antipsychotic.' As can be seen in Figure 2, there is a 
significant downward trend ofTRx for Zyprexa and a counter-balancing upward trend of 
TRx for Seroquel. The TRx trending for the other three antipsychotics in relation to 
Zyprexa and Seroquel, by and large, stayed the same. Because the total market (as 
displayed in Figure 1) was stable over this timeframe, the data suggest that physicians 
primarily shifted prescribing amongst the two autipsychotics Zyprexa and Seroquel. 
Although more months of data will need to be observed to completely characterize the 
impact of the CATIE study, there does not seem to be a significant shift in the prescribing 
trends based on reporting of study results. 
• Please note that the monthly fluctuations in TRx that can be seen for the individual antipsychotics are 
normal and are caused by a varying number of working days in any given month (e.g., length of the month, 
holidays). 
Page 9 of37 
700,000 
600,000 
500,000 
X 400,000 1!: 
300,000 
200,000 
100,000 
0 
Figure 2- Individual Antipsychotic TRx January 2002 to December 2005 
Media reports or; sludy res~lls 
queslioning Iyp!e~a >:1fficaq 
Month 
Source: Verispan VONA, Antipsychotics, Feb 2006 
F orlhcomi,.q resu~s of NIMH 
31udy repQrt>:td o-r1 b-y N!H 
Figure 3 presents similar data for the individual antipsychotics represented as 
percent market share at each of the seven major media communications time points. 
Perphenazine 
What can be seen from this graphic is a significant shift in market share between Zyprexa 
and Seroquel. In January 2002, Zyprexa was second to Risperdal in market share with a 
15 .l% margin separating it from Seroquel, the third highest prescribed antipsychotic. By 
September 2005, Zyprexa's market share had fallen and it became the third highest 
prescribed antipsychotic, supplanted by the surging Seroquel. A 19.3% margin in favor 
of Seroquel now separated Zyprexa and Seroquel. In total, Zyprexa experienced a 34.4% 
loss in market share to Seroquel during this time period. 
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Figure 3- Antipsychotic Market Share (% of TR:x) for Each of the Major Media 
Communications Time Points 
Source: Verispan VONA, Antipsychotics, Feb 2006 
Discussion 
The results ofthis analysis demonstrate a significant shift in prescribing behavior 
away from Zyprexa that appears to be well correlated with the timing of negative press 
regarding the associated weight gain. While all other antipsychotics benefited from this 
shift away from Zyprexa by either increasing prescriptions (Abilify, Geodon) or 
stemming a downward trend (Risperdal), Seroquel prescribing increased the most 
substantially over the time period. We suspect that the shift to Seroquel was largely 
based on the combination of a more favorable side effect profile coupled with an 
aggressive clinical program to expand product indications/uses. 9 
Despite all of the negative press regarding atypical antipsychotics, perphenazine 
experienced a slight loss in market share of approximately 1% which suggests that the 
neurological side effects associated with first generation antipsychotics (e.g., 
extrapyramidal signs and tardive dyskinesia) are sufficiently common and problematic 
that physicians did not shift behavior away from the atypical agents upon publication of 
evidence associating weight gain with the second generation agents or the equivalent 
efficacy data demonstrated with agents other than Zyprexa in the CATIE study. 10 
One limitation of this analysis was that Verispan data was not available until 
January 2002, one year after the initiation of the CATIE study. Although this analysis 
Page II of37 
could not parallel the conduct ofthe CATIE study, the analysis of the communication 
literature suggests that there were no substantial media events that occurred between 
January 2001 and January 2002 that would likely have had an effect on prescribing. 
Another limitation of this analysis is the lack oflonger-term data following the 
publication of the CATIE study results in September 2005. Although the data is limited, 
the trend information exhibited in the few months post September 2005 is suggestive of a 
continuation of stabile TRx volume through December 2005. It is difficult to discern, 
however, whether the share of individual products has continued on previous trends or, 
perhaps, whether there is a modest stabilization in the shift in share between Zyprexa and 
the other second-generation products. 
As a follow-up to this analysis, it would be interesting to track further market 
behavior in the wake of the release of the CATIE study results as psychiatrists anticipate 
the release of the next round of results, scheduled for 2006. This follow-up analysis 
should start with Verispan prescription data from January 2006 once it becomes 
available. The publishing of the CATIE study results on September 22, 2005 included 
only top-line analysis of the data. Perhaps psychiatrists are eagerly awaiting the 
publication of subsequent analyses from this landmark study before actually 
implementing changes in their patient care and prescribing habits. 
Conclusion 
The analysis presented in this paper demonstrates the potential for clinical data to 
impact physician prescribing behavior. In this case, however, the information suggests 
that the more significant change in antipsychotic market prescribing behavior was 
brought on by media events surrounding the adverse side effects associated with top-
selling atypical antipsychotics in 2003 rather than the release of study results from the 
CATIE Schizophrenia Study in September 2005. 
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Case Study 2- Contraceptives 
Introduction 
Clinical trials conducted in support of a New Drug Application are primarily 
randomized controlled trials conducted in narrowly defined patient populations as 
directed by regulatory requirements. The result of the stringent inclusion/exclusion 
criteria, limited size and diversity of the patient population being studied, combined with 
the short duration of Phase III studies limits the amount of data available on a drug's 
safety profile. 1 As a result, many serious safety issues only come to light after the 
product has been approved and used more widely both in terms of patient exposures and 
demographics. Two recent, highly publicized instances of unanticipated side effects 
ultimately resulting in product withdrawal include Merck's Vioxx and Biogen/Eian's 
Tysabri. Many other products have not been withdrawn, but rather have been the subject 
of Dear Doctor letters and Black Box Warnings; Ortho Evra is one such example of this 
type of product. 
Ortho Evra, a product of Johnson & Johnson subsidiary Ortho-McNeil 
Pharmaceutical, was approved in November 20, 2001 as a once-a-week contraceptive 
patch for women. It was and still is the first transdermal hormonal patch to be approved, 
as well as the first non-invasive form of birth control that, when used correctly, is 99% 
effective. The Ortho Evra patch is worn for seven days releasing the hormones 
progesterone and estrogen directly into the blood before being replaced, for three weeks. 
The fonrth week is treatment free, as with oral contraceptives.2 
Deemed a "wonder drug" when it was launched with much fanfare and glitzy 
advertising in March 2002, Ortho Evra was touted as the most revolutionary drug after 
the oral contraceptive pill. In 2004, Ortho Evra prescriptions totaled more than 9.9 
million with sales topping $411 million. 3 However, an Associated Press investigation 
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published in July 2005 reported that women on the Ortho Evra patch were three times 
more likely to die or be injured by a blood clot than women on the pill. The AP used the 
Freedom of Information Act to obtain adverse drug reaction reports for Ortho Evra from 
the Food and Drug administration (FDA) and reportedly found that out of the 23 cases in 
which death was the outcome, physicians reviewing the cases found 17 that appeared to 
be blood-clot-related, including 12 cases from 2004. The first fatality publicly blamed on 
Ortho Evra carne in April2005, when an autopsy found a blood clot had moved into the 
victim's lung and the medical examiner ruled that the clot was a side effect of the 
contraceptive patch that she was currently taking. FDA records show that 17 patch users 
between the ages of 17 and 30 years of age have suffered fatal heart attacks, blood clots, 
and possible strokes since August 2002 4 
· The initial merits of Ortho Evra were its mechanism of aCtion whereby hormones 
are absorbed directly into the bloodstrean1, avoiding metabolism through the digestive 
system. Although this mechanism of action was initially considered to contribute to 
increased efficacy, it may ultimately have been Ortho Evra' s downfall from a safety 
perspective due to prolonged exposure to a high dose of estrogen in the circulatory 
system. In comparison, oral contraception is taken orally and enters the digestive tract 
first, with 50% of the estrogen being eradicated through the digestive system within a few 
hours of taking the pill.5 
On November 10,2005, the FDA announced and Ortho McNeil confirmed the 
approval of updated labeling for Ortho Evra, warning healthcare providers and consumers 
about the increased risk. The move was a result of the FDA's review of two sponsor-
funded studies directly comparing the levels of estrogen in users of Ortho Evra with those 
using a typical oral contraceptive. The analysis showed that women who use Ortho Evra 
might be exposed to 60% more estrogen than those using a typical birth control pill, 
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which contains 35 micrograms of estrogen. Higher levels of estrogen may put some 
women at increased risk for getting blood clots.6 In the same announcement, the FDA 
indicated that Ortho McNeil is currently conducting studies to evaluate the risks of 
developing serious blood clots in women using Ortho Evra versus the risks caused by 
traditional birth control pills. 
The FDA, however, does not know if women using Ortho Evra are at a higher risk 
for serious side effects than if they are using a traditional birth control pilL There is 
currently no epidemiological data available to determine whether safety and efficacy with 
the transdermal route of administration would be different than with the oral route. As a 
result of this predicament and in addition to the fact that the safety of medications 
delivered by the mechanism oftransdermal patches seemingly present common 
problems, on March 2, 2006 the FDA announced that it would launch an "exhaustive 
review" regarding the safety of medicated patches, including Ortho Evra.7 
In the wake of the FDA and Ortho-McNeil press releases and the FDA advisory, 
The Wall Street Journal (WSJ) reported on November 22, 2005 that there have been 
several reports of physicians and other healthcare providers curtailing or suspending the 
prescribing of Ortho Evra to patients. The WSJ reported that some physicians and health 
care providers "don't want to take any chances" with Ortho Evra and are no longer 
offering new prescriptions. Others are advising their patients who currently are using 
Ortho Evra to switch to another form ofbirth controL 7 
To examine the impact ofthe FDA's action as well as publicity from the general 
press, this analysis examines prescribing habits over a four-year period, starting two 
months after Ortho Evra's 2001 regulatory approval and continuing through January 
2006, following communication of safety concerns. 
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Methods 
The approach to investigating the impact of widespread publicity regarding the 
safety ofOrtho Evra consisted of two activities: I) identification of the key 
communications surrounding safety concerns with Ortho Evra and, 2) time series analysis 
of TRx data for Ortho Evra in isolation, and in comparison to three other oral 
contraceptive launch brands during the January 2002 to January 2006 timeframe-
Yasmin (pill), Ortho Tri-Cyclen Lo (pill), and Seasonale (pill). By selecting another 
Johnson & Johnson product, Ortho Tri-Cyclen Lo, as one of the comparison brands, we 
are also able to examine the impact on Ortho Evra independent of promotional resources. 
January 2002 was chosen as a starting point for the analysis since 2002 is the year 
that Ortho Evra sales began, with product launch occurring two months after this date. 
January 2006 was selected as the end date because it was the most recent month of data 
available. 
Total prescriptions (TRx) and market share(% ofTRx) were obtained from 
January 2002 through January 2006 for the four contraceptive products of interest. 
Generic and "branded" generic contraceptives were not included in this analysis in order 
to eliminate confusion surrounding the conversion of patients from the brand name 
product to generic products. By including only branded products, the analysis focuses 
solely on products being actively promoted by sales representatives to support market 
share growth. 
To identifY media communications surrounding Ortho Evra, an Internet search 
was conducted in Google to identifY media events in the November 2001 to March 2006 
timeframe using the terms "Ortho Evra" (see Attachment C). Articles or references to 
articles contained within the following formats were excluded: 
• Personal blogs (articles from "periodical type" blogs were included) 
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• Listings of ongoing litigation 
• Articles not written in English 
Results 
Publicity on Safety of Ortho Evra 
The analysis of media events identified eight major communications that could 
potentially influence physician-prescribing behavior: 
• Birth-control patch may have higher risk, July 16, 2005 
• FDA Updates Labeling for Ortho Evra Contraceptive Patch; New Prescribing 
Information Announced For Ortho Evra® Birth Control Patch, November 10, 2005 
• Birth Control Patch Users Warned, November 11, 2005 
• Some Doctors Stop Prescribing Ortho Evra Birth Control Patch After FDA Warning, 
Wall Street Journal Report, November 22, 2005 
• Results Of Two Epidemiological Studies Provide Important New Clinical Information 
About The Safety OfORTHO EVRA®, February 16,2006 
• Birth-Control Patch Users Risk Blood Clots, February 17,2006 
• Clot Risk for Birth-Control Patch Is Found to Be Double That of Pill, February 18, 
2006 
• Warning issued for Ortho Evra birth contrOl patch, Februruy 21, 2006 
As can be seen from the dates of the communications listed above, reporting on 
the safety issues regarding Ortho Evra were still very much unfolding at the time that this 
paper was written. The Associated Press article on Ortho Evra users being at higher risks 
of blood clots in July 2005 was the first major media report found regarding the Ortho 
Evra safety concerns. This article was based on FDA adverse drug reaction reports for 
Ortho Evra obtained by the AP through the Freedom ofinformation Act. The AP 
focused on data from 2004, when Ortho Evra's popularity was at its peak. Starting in 
November 2005 with the FDA advisory on the Ortho Evra label change and continuing 
through the present day with the FDA's announcement that they will be reviewing the 
safety of all types of medicated patches, including Ortho Evra, the publicity regarding 
this issue has been very prominent and widespread in the popular press. 
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Prescription Data 
Figure 1 presents total prescriptions (TRx) from January 2002 to January 2006, 
inclusive, for all female contraceptives, excluding condoms, graphed concurrently with 
the timing of four of the eight key data communications listed above. Since the most 
current month ofV erispan data available for this analysis was January 2006, four of the 
eight communications listed above post-January 2006 could not be graphed. 
Additionally, although it was not identified as a standalone communication in the Internet 
search for this analysis, a time point for the first fatality publicly blamed on Ortho Evra 
that was reported, April2005, has been added to Figures 1 and 2 as the event was 
referred to in one of the identified communications. A time point for the commercial 
launch of Ortho Evra in March 2002 has been added to Figures 1 and 2 as a reference. 
As can be seen in Figure 1, TRx for contraceptives has been steady at around 
8,000,000 prescriptions per year for the 2002 to early 2006 timeframe, which suggests 
that much of the change in volume across agents observed during this timeframe is really 
a shift in prescribing behavior among products rather than an expansion in the market 
SIZe. 
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Figure 2 presents total prescriptions (TRx) from J ~uary 2002 to January 2006, 
inclusive, for the four contraceptive products commercially launched between 2001 and 
2003: Yasmin, Ortho Tri-Cyclen Lo, Ortho Evra, and Seasonale. As can be seen in 
Figure 2, there is a significant downward trend ofTRx for Ortho Evra post-May 2005, 
one month after the first fatality publicly blamed on Ortho Evra was reported. This 
downward trend continued and even increased in rate through January 2006. Noticeably, 
the TRx trending for Ortho Tri Cyclen Lo and Yasmin in relation to Ortho Evra basically 
stayed the same. Both products continued their steady upward trends in TRx post-launch 
and it can be noted that these trends are very similar to one another and both represent a 
standard TRx growth rate for a newly marketed contraceptive. Ortho Evra, on the other 
hand, experienced an explosive growth rate between its launch in March 2002 through 
August 2004, when it was at the height of its popularity. This non-standard trend in TRx 
growth rate is most likely a result of the aggressive marketing campaign initiated by 
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Johnson & Johnson that accompanied the product's launch as well as the popularity 
stemming from the novelty of a contraceptive patch, the first and still only one of its kind. 
The downward trending ofOrtho Evra TRx post-May 2005 through January 2006 
and the lack of accelerated growth of the Ortho Tri Cyclen Lo and Y asmin growth rate in 
response indicates that consumers were not switching to either one of these products but 
rather to other older, generic contraceptive methods with more robust longitudinal safety 
data. Further investigation on this point is warranted in order to draw any definitive 
conclusions regarding specific products that may have benefited from the Ortho Evra 
decline. Retail pharmacy data post-January 2006 needs to be observed in order to more 
fully characterize the impact of the publicity regarding Ortho Evra; including mapping 
the four remaining media communications that were unable to be graphed due to data 
constraints. However, as can be seen from Figure 2, Ortho Evra TRx. began trending 
downward in May 2005 and increased in rate of decline in October 2005, continuing 
through the data cut-offin January 2006. Since this pattern of decline has been in motion 
now for over nine months, and it is likely that the additional communications mentioned 
previously will only continue to sustain or perhaps accelerate further this trend, one can 
safely conclude that there does seem to be a significant shift in the prescribing trend of 
Ortho Evra based on this publicity regarding safety concerns. 
Page 21 of37 
1000 
900 
800 
.!!. 700 
X 600 !~ 500 
400 
300 
200 
100 
0 
Figure 2- Individual Contraceptives TRx January 2002 to January 2006 
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Source: Verispan VONA, Contraceptives, Feb 2006 
Figure 3 presents similar data for the four contraceptive products represented as 
percent share between each of the four products. What can be seen from this graphic is a 
significant decline in share for Ortho Evra. In May 2005, Ortho Evra was ranked second 
to Yasmin by a small margin. It was separated by a 9.5% margin from the other Johnson 
& Johnson launch brand, Ortho Tri Cyclen Lo, which was ranked number 3 of 4 of the 
branded products at the time. By the end of January 2006, Ortho Evra had fallen to 
number 3 behind number 2 ranked Ortho Tri Cyclen Lo, separated by a 4% margin. 
Ortho Evra lost a total of 10 percentage points in share compared to the other three 
products over this nine-month period. 
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Figure 3- Contraceptives Share(% ofTRx) May 2005 to January 2006 
Source: Verispan VONA, Contraceptives, Feb 2006 
Discussion 
The results of this analysis demonstrate a significant shift in prescribing behavior 
away from Ortho Evra that appears to be well correlated with the timing of negative press 
regarding its safety. While the other three contraceptive products do not appear to have 
benefited directly from this shift in prescribing activity, it is likely that other older, 
. generic birth control methods with more comprehensive safety data have benefited with 
slight increases in market share. 
The trend information exhibited in the wake of the reporting in April2005 of the 
first fatality publicly blamed on Ortho Evra is suggestive of a significant shift in 
prescribing activity, which is continuing at the present time. One limitation ofthis 
analysis was that Verispan data was not available after January 2006, which is when half 
of the identified communications that could potentially influence physician-prescribing 
behavior were released. However, as Figure 2 demonstrates the downward trend in TRx 
for Ortho Evra was set in motion eight months prior to the data cut-off for this analysis, 
in May 2005. So, there was substantial data available from which to base this conclusion. 
As a follow-up to this analysis, it would be interesting to track further the continuing 
behavior in TRx for these four contraceptive products in the months post-January 2006 to 
assess the impact of the FDA's review of medicated patches, reported on in March 2006, 
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as well as the continuing publicity regarding the safety concerns of Ortho Evra, released 
seemingly on a daily basis. 
Conclusion 
The analysis of contraceptives presented in this case study demonstrates the 
potential for publicity surrounding safety concerns of a marketed product to impact 
physician prescribing behavior. The information suggests a significant shift in physician 
prescribing behavior in response to negative publicity regarding the safety of Ortho Evra. 
However, as was demonstrated in the first case study, the information suggests that the 
more significant change in contraceptive prescribing behavior was brought on by the 
initial media event in July 2005 surrounding the increased risk of blood clots for users of 
Ortho Evra, rather than the FDA and Ortho-McNeil press releases and the FDA advisory 
released in November 2005. 
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Conclusion 
The analyses presented in this paper have demonstrated that physician-prescribing 
behavior for both antipsychotics and contraceptives, two therapeutic categories with very 
different prescribing bases, was influenced by media events but not the events that were 
initially targeted in each analysis; the publication of the CA TIE study results and the 
FDA's advisory on updated labeling for Ortho Evra. In both case studies, the impact on 
physician-prescribing behavior was pre-empted by earlier mass media events regarding 
adverse side effects associated with top-selling atypical antipsychotics, specifically 
Zyprexa, and the increased risk of blood clots for users of Ortho Evra. Nevertheless, both 
analyses demonstrate that the media, in one form or another has the capability of 
permeating physician practice as demonstrated by physicians within both of these 
therapeutic classes. 
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Attachment A 
Log of NIMH Schizophrenia Study-Related Media Events dul"ing the Time Period January 2001- March 2006 
-· 
Search Text Article Author Date 
"Dr. Jeffrey The Next Phase in Psychiatry: Largest Ever Studies on Drugs for Depression, The Wall Street Journal 7/27/05 
Lieberman+ Schizophrenia Could Transform Treatment 
CATIE" 
Link: http://www.paxilQrogress.org/forums/showthread.php?t-12839 (alternate link to free copy of article) 
"Dr. Jeffrey CATIE Study- New Schizophrenia Treatment Standards Coming Schizophrenia Daily 7/27/05 
Lieberman+ NewsBlog 
CATIE" 
Link: httQ:/ /www .schizophrenia.com/sznews/archives/002172.html 
"Dr. Jeffrey Next Phase in Psychiatry? Or, NIMH Effort to Rescue Bad Drugs- WSJ Alliance for Human 7/29/05 
Lieberman+ Research Protection 
CATIE" 
. 
Link: httQ ://www .ahro.org/infomail/05/07 /29a.phQ 
"Dr. Jeffrey Study Shows Older, Cheaper Drug is Effective as Newer Antipsychotic Meds National Institutes of 9/2005 
Lieberman+ Health 
CATIE" 
Link: httQ://www.nih.gov/news/radio/sep2005/09252005catie.htm 
"Effectiveness of NIMH study to guide treatment choices for schizophrenia Medical News Today 9/10/05 
Antipsychotic 
Drugs in Patients" 
Link: htto:/ /www.medicalnewstoday.com/medicalnews.phQ?newsid~30861 
"Effectiveness of Study finds old, new schizophrenia drugs about equal I Science Blog 19/19/05 
Antipsychotic 
Drugs in Patients" 
Link: htto://www.scienceblog.com/cms/study finds old new schizophrenia drugs about egual 8936 
"Effectiveness of Zyprexa Edges Four Other Agents With Modest Benefit focr Schizophrenia I Medpage Today 1 9/19/05 
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Antipsychotic 
Drugs in Patients" 
Link: httQ :/ /www .medQagetoday. com/Psychiatry/GeneralPsychiatry/tb/1 7 58 
"Dr. Jeffrey Landmark UNC-led schizophrenia study finds older drug comparably effective to newer The University of North 9/19/05 
Lieberman+ drugs Carolina at Chapel Hill 
CATIE" 
Link: ht!Q :/ /www. unc. edu/news/ archives/ seQ05 I catie091905 .htm 
"Dr. Jeffrey Schizophrenia Drugs Still Fall Short Healthfinder 9/19/05 
Lieberman+ Newer ones not much more effective than older medicines, a new study finds. 
CATIE" 
Link: htto://www.healthfinder.gov/news/newsstory.asQ?dociD=528062 
"Dr. Jeffrey Study finds no best schizophrenia drug The Arizona Republic 9/19/05 
Lieberman+ 
CATIE" 
Link: httQ :/ /www. azcentral.comlhealth/wellness/ articles/0919sch-CR.html 
"Dr. Jeffrey Differences seen in anti-psychotic drugs Monsters and Critics 9/19/05 
Lieberman+ 
CATIE" 
Link: httQ://news.monstersandcritics.com/health/article 1 049163.J2hQ/Differences seen in anti-Qsychotic drugs 
"Effectiveness of Are Anti-psychotic Medications All the Same? Dare to Dream 9/19/05 
Antipsychotic 
Drugs in Patients" 
Link: httQ :1/dej .us/mt/archives/mental health treatment/antiQsychotic medication/ 
"Effectiveness of NIMH study to guide treatment choices for schizophrenia EurekAlert 9/19/05 
Antipsychotic 
Drugs in Patients" 
Link: htto:/ /www.eurekalert.org/oub releases/2005-09/niom-nst091905 .QhQ 
"Effectiveness of CATIE Results- Perphenazine almost as good as newer drugs Schizophrenia Daily 9/20/05 
Antipsychotic NewsB!og 
Drugs in Patients" 
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Link: htto :/ /www. schizoohrenia.com/ sznews/ arc hi ves/002424 .html 
"Effectiveness of DON'T BE A BIG PHARMA VICTIM -USE COMMON SENSE Dr. Carolyn Dean, MD, 9/20/05 
Antipsychotic NDand 
Drugs in Patients" Elissa Meininger 
Link: httQ:/ /www.newswithviews.com/Dean/carolytl16.htm 
"Dr. Jeffrey Study Finds Little Advantage In New Schizophrenia Drugs I The New York Times 19/20/05 
Lieberman+ 
CATIE" 
Link: htto://Qsychrights.org/ Articles/NYTimesAtYQicalsnobetter.html 
"Effectiveness of Antipsychotics- Newer Is Not Always Better Clinical Cases and 9120105 
Antipsychotic Images - Blog 
Drugs in Patients" 
Link: httQ://casesblog.blogsQot.com/2005/09/antiQsychotics-newer-is-not-always.html 
"Dr. Jeffrey Tough Choices in Treating Schizophrenia National Public Radio 9/20/05 
Lieberman+ 
CATIE" 
Link: htto://www.nQr.org/temQlates/story/story.QhQ?storvid=4855599 
"Dr. Jeffrey Old schizophrenia drugs as good as new I myDNA 19/20/05 
Lieberman+ 
CATIE" 
Link: htto://www.mydna.com/resources/meds/resources/news/200509/news 20050920 schrx.html 
"Effectiveness of STUDY FINDS LITTLE ADVANTAGE IN NEW SCHIZOPHRENIA DRUGS National Center for 9/21105 
Antipsychotic Policy Analysis 
Drugs in Patients" 
Link: httQ://www.ncQa.org/newdQd/dQdarticle.QhQ?article id=2277 
"Effectiveness of Meds Alert: Old schizophrenia drug stands up to new ones Science News Online 9/24/05 
Antipsychotic 
Drugs in Patients" 
Link: httQ :/ /www.sciencenews.org/articles/20050924/fob lref.as2 
"Dr. Jeffrey NIMH study to guide treatment choices for schizophrenia I PsychLinks Online 1 9127105 
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Lieberman+ Psychology Forum 
CATIE" 
Link: ht!Q://www.J2sychlinks.ca/]2h]2bb/viewto]2iC.J2h]2?t=3029& 
"Effectiveness of National Institute of Mental Health Study Compares CAREMARK- Trends 9/30/05 
Antipsychotic Treatments for Schizophrenia Rx - Drug Pipeline and 
Drugs in Patients" News 
Link: ht!Q :/ /www .caremark.cornl]2ortal/ asset/PiQeline-SeQtember 3 0. Qdf 
"Dr. Jeffrey Differences Seen In Anti Psychotic Drugs Applesforhealth.com 9/30/05 
Lieberman+ 
CATIE" 
Link: httQ://www.aQJ2lesforhealth.com/Menta1Health/dsaQd7.html 
"Effectiveness of AP A Says CA TIE Schizophrenia Study Argues for Full Range of Treatment Options PedsCare Children's 10/2005 
Antipsychotic Mental Health Initiatives 
Drugs in Patients" 
Link: httQ:/ /www.aaJ2.org/commJ2eds/dochs/mentalhealth!MH -OCT2005 .Qdf 
"Effectiveness of Most patients taking second-generation (atypical) antipsychotic drugs discontinued their Wonca Online 10/4/05 
Antipsychotic treatment because of inefficacy or intolerable side effects, or for other reasons 
Drugs in Patients" 
Link: httQ://www.globalfamilydoctor.com/search!GFDSearch.asJ2?itemNum-4647 
"Effectiveness of Top Abstracts in Schizophrenia I 0/06/2005 . I Doctor's Guide 110/6/05 
Antipsychotic 
Drugs in Patients" 
Link: htt]2:/ /www.docguide.com/news/content.nsf/news/34ED8BD7D55E8EC3 85257093000C5314 
"Effectiveness of CATIE Comes To Surprising Conclusions I Schizophrenia Research 110/16/05 
Antipsychotic 
Drugs in Patients" 
Forum 
Link: htto://www.schizoQhreniaforum.org/new/detail.asQ?id=l1_9fl. 
"Effectiveness of Comments on Paper and Primary News Schizophrenia Research 10/18/05 
Antipsychotic Forum 
Drugs in Patients" *Comments by mostly MDs on the study paper via the article listed above. 
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Link: http://www. schizoJ:lhreniaforum.org/QaJ:l/ annotation. as12 ?QoW ID=5 9284 
"Effectiveness of Goverument Antipsychotic Study Finds No Clear Winner in 'Horse Race' Psychiatric News 10/21/05 
Antipsychotic 
Drugs in Patients" 
Link: httQ://Qn.Qsychiatryonline.org/cgi/content/full/40/20/1 
"Effectiveness of Antipsychotics in the elderly: Reducing risks of stroke and death Current Psychiatry 1112005 
Antipsychotic Online 
Drugs in Patients" 
Link: htto://www.currentosychiatry.com/article Qages.asQ? AID=2825&UID= 
"Effectiveness of Little Difference Found in Schizophrenia Drugs Caring and Sharing 1112005 
Antipsychotic 
Drugs in Patients" 
Link: httQ ://www .narni12hoenix. org/SchizoJ:lhreniaDrugs.html 
"Effectiveness of Effectiveness of antipsychotic drugs for chronic schizophrenia investigated I NewsRx 111/7/05 
Antipsychotic 
Drugs in Patients" 
Link: htt]2:1/www.newsrx.com/issue article/5W/2005-ll-07/11 07200533313335W.html 
"Effectiveness of Top Abstracts in Schizophrenia 11117/2005 I Doctor's Guide 111117/05 
Antipsychotic 
Drugs in Patients" 
Link: htt]2://www.docguide.com/news/content.nsf/news/745A6736C255DC2C852570BD00116AB4 
"Effectiveness of National Council Response to CA TIE Study on Antipsychotics National Council for 2005 
Antipsychotic Community Behavioral 
Drugs in Patients" Healthcare 
Link: htto://www.nccbh.org/WHO/INDUSTRY/CATIE.HTM 
"Effectiveness of Prescribing Review- Drugs Used in Mental Health I NHS Prescription Pricing I UNK 
Antipsychotic 
Drugs in Patients" 
-----
Authonty 
Link: httQ ://www .QQa.org. uk/news/Qact-092005 .htm 
"Effectiveness of Report on the Escalating International I Citizens Commission on IUNK 
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Antipsychotic Warnings on Psychiatric Drugs Human Rights (EC!ub) 
Drugs in Patients" 
Link: htto://www.camQaiggfortruth.com/Eclub/241005/CTM%20-%20ADHD%20drugs%20don't%20work.htm 
"Effectiveness of Report on the Escalating International W amings on Psychiatric Drugs Citizens Commission on 
Antipsychotic Human Rights 
Drugs in Patients" International 
Link: httQ://h1l.Qrotectedsite.net/files/8011/drug reQort.Qdf 
"Effectiveness of Newer antipsychotics similar to older agents (CATIE) InfoPOEMs- The 
Antipsychotic Clinical Awareness 
Drugs in Patients" System 
Link: httQ :/ /www.infoQoems.com/infoQoems/showPOEM.cfm ?ID=711 05 
"Dr. Jeffrey Lost In Translation: What We Really Learned From CA TIE Psychiatric News 
Lieberman+ 
CATIE" 
Link: httQ :/ /Qn. Qsychiatryonline.org/ c gi/ content/full/ 41 I 1/20 
"Dr. Jeffrey Dr. Lieberman and Colleagues Reply American Journal of 
Lieberman+ Psychiatry 
CATIE" 
Link: htto:/ /ajQ.QSychiatryonline.org/cgi/content/full/163/3/5 55-a . 
"Dr. Jeffrey The CA TIE Study I American Journal of 
Lieberman+ 
CATIE" 
Psychiatry 
Link: htto://ajQ.Qsychiatryonline.org/cgi/content/full/163/3/554 
-- -· 
ARTICLES OR REFERENCE TO ARTICLES CONTAINED WITHIN THE FOLLOWING FORMATS WERE EXCLUDED: 
personal blogs (articles from "periodical type" blogs were included), listings of ongoing clinical trials (unless preliminary results were 
mentioned as a part of the listing), listings of the article and/or abstract itself, listings of ongoing litigation, speal(ing engagement 
announcements where the article is referenced, articles in non-English languages. 
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Attachment B 
Log of Media Events Related to Zyprexa and Weight Gain during the Time Period January 2001- March 2006 
Search Text Article Author Date 
"Weight Gain+ Increased Prevalence of Diabetes Among Patients Receiving Antipsychotic Drugs HealthyPlace.com 5/20/03 
Zyprexa" 
Link: httu://www.healthJIIllace.com/Communities/Thought Disorders/schizo/news/diabetes antiusychotics.asu 
"Weight Gain+ Most Atypical Antipsychotics Tied to Increase in Diabetes I HealthyPlace.com 18/22/03 
Zyprexa" 
Link: htill :/ /www .health Jill lace. com/Communities/Thought Disorders/ schizo/news/ diabetes antiusychotics 2. asu 
"Weight Gain + FDA Seeks Diabetes Warning on All Antipsychotic Drugs I HealthyPlace.com 19118/03 
Zyprexa" 
Link: httu://www.healthJIIllace.com/Communities/Thought Disorders/schizo/news/diabetes antiusychotics 3.asu 
"Weight Gain + Weight Gain is Potential Problem in Patients Switched from Risperidal to Zyprexa HealthyPlace.com 10/16/03 
Zyprexa" 
Link: httu://www.healthJIIllace.com/Communities/Thought Dis()r~ers/schizo/news/weight gain antiusychotics 2.asu 
"Weight Gain + Atypical Antipsychotic Drugs Linked to Diabetes HealthyPlace.com 11/3/03 
Zyprexa" 
Link: httu://www.healthJIIllace.com/Communities/Thought Disorders/schizo/news/diabetes antiusychotics 4.asu 
"Weight Gain + Zyprexa Efficacy Questionable Online Lawyer Source 11/25/03 
Zyprexa" 
Link: httu://www.onlinelawyersource.com/news/zJIIlrexa.html 
"Weight Gain + Eli Lilly and Co. Shares Fall Following Zyprexa Study Online Lawyer Source 11126/03 
Zyprexa" 
Link: httu://www.onlinelawyersource.com/news/zJIIlrexa2.html 
"Weight Gain + Antipsychotic Drugs Raise Diabetes Risk I HealthyPlace.com 11127/04 
Zyprexa" 
Link: httQ :/ /www .health Jill lace. com/Communities/Thought Disorders/ schizo/news/ diabetes antiusychotics 5. asu 
"Weight Gain+ Diabetes Risk Increased by Antipsychotic Drugs I Online Lawyer Source 11128/04 
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Zyprexa" 
Link: httQ ://www .onlinelawyersource.com/news/zYQrexa4.html 
"Weight Gain + Elderly Warned of Off-Label Zyprexa Use Online Lawyer Source 2/10/04 
Zyprexa" 
Link: httQ ://www.onlinelawyersource.com/newslzYQrexa5 .html 
"Weight Gain + Zyprexa Lawsuits Filed Due to Serious Cases of Diabetes and Pancreatitis Online Lawyer Source 3/19/04 
Zyprexa" 
Link: htto://www.onlinelawyersource.com/news/zYQrexa-diabetes,html 
"Weight Gain+ Zyprexa Class Action Lawsuit Announced Online Lawyer Source 4/19/04 
Zyprexa" 
Link: httQ ://www. onlinelawyersource. com/newslzYQrexa-lawsuit.html 
"Weight Gain + Nationwide Zyprexa class action lawsuit filed Defective Drugs 5/21/04 
Zyprexa" . Adrugrecall.com 
Link: httQ://www.adrugrecall.com/newsletter/jun04/zYQrexa.h!ml 
"Weight Gain + Zyprexa Sales Hurting Because of Safety Concerns Online Lawyer Source 7/8/04 
Zyprexa" 
Link: httQ://www.onlinelawyersource.com/news/zYQrexa-safety.html 
"Weight Gain+ Eli Lilly Sued for Its Zyprexa Drug Online Lawyer Source 7/31/04 
Zyprexa" 
Link: httQ://www.onlinelawyersource.com/news/zYQrexa-claim.htnil 
"Weight Gain + Antipsychotics linked to serious adulthood diseases Defective Drugs 10/25/04 
Zyprexa" Adrugrecall.com 
Link: htto://www.adrugrecall.com/newsletter/nov04/zYQrexa--safety.html 
"Weight Gain + Eli Lilly using legal tactic to stall Zyprexa lawsuits I Online Lawyer Source 111/7/04 
Zyprexa" 
Link: httQ://www.onlinelawyersource.com/news/zYQrexa-legal.html 
"Weight Gain + Zyprexa lawsuit on behalf of Canadians filed Defective Drugs 2/5/05 
Zyprexa" Adrugrecall.com 
. 
Link: htto://www.adrugrecall.com/newslzYQrexa-lawsuit.html 
.. 
"Weight Gain + Zyprexa warning issued Defective Drugs 4/11105 
. 
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---· I Adrugrecall.com Zyprexa" 
Link: htto://www.adrugrecall.com/news/zY];lrexa-warning.html 
"Weight Gain + Elderly patients warned of Zyprexa risks I Defective Drugs 
Zyprexa" Adrugrecall.com 
Link: http://www.adrugrecall.com/news/zY];lrexa-e1derly.html 
·-· 
"Weight Gain + Zyprexa linked with Diabetes National Alliance for the 
Zyprexa" Mentally Ill- Santa Cruz 
County 
Link: http://www.namiscc.org/News/2003/Sunnner/ZYl)rexaLinkToDiabetes.htm 
"Weight Gain+ Zyprexa Weight Gain: Medical Information Monheit Law 
Zyprexa" 
Link: http://www.monheit.com/zY];lrexalmedical.shtml 
"Weight Gain+ Zyprexa Weight Gain I Online Lawyer Source 
Zyprexa" 
Link: htto://www.onlinelawyersource.com/zYl)rexa/weight.html 
"Weight Gain + The Side Effects of Zyprexa May Be Deadly I Class Action America 
Zyprexa" Online 
Link: htto://www.classactionamerica.com/Current-Cases/zY];lre_xa-side-effects.asp 
"Weight Gain + Zyprexa Warning I Defective Drugs 
Zyprexa" 
-
Adrugrecall.com 
Link: htto://www.adrugrecall.com/zY];lrexa/warning.html 
"Weight Gain+ Zyprexa Medicaid Gravy Train Derailed I OpEdNews.com 
Zyprexa" 
Link: http://www.opednews.com/articles/genera evelyg p 060221 zYl)rexa medicaid gra.htm 
ARTICLES OR REFERENCE TO ARTICLES CONTAINED WITHIN THE FOLLOWING FORMATS WERE EXCLUDED: 
personal blogs (articles from "periodical type" blogs were included) and articles in non-English languages. 
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Attachment C 
Log of Media Events Related to Ortho Evra during the Time Period January 2002- March 2006 
Search Text Article Author Date 
Ortho Evra FDA Approves First Hormonal Contraceptive Skin Patch Food and Drug 11120/01 
Administration 
Link: httQ ://www .fda.gov/bbs/toQics/ ANSWERS/200 11 ANSO 1119 .html 
Ortho Evra First Birth Control Patch, OR THO EVRA ™ (norelgestromin/ethinyl estradiol Johnson & Johnson 4/30/02 
transdermal system) Now Available by Prescription 
Link: httQ://www.jnj.com/news/jnj news/20020430 1425.htm 
Ortho Evra Birth-control patch may have higher risk Associated Press 7/16/05 
(reported by The Boston 
Globe) 
Link: httQ://www.boston.com/yourlife/health/women/articles/2005/07/16/birth control Qatch may have higher riski?Qage=full 
Ortho Evra FDA Updates Labeling for Ortho Evra Contraceptive Patch (Press Release) Food and Drug 11110/05 
Administration 
Link: httQ://www.fda.gov/bbs/toQics/news/2005/NEW01262.html 
Ortho Evra New Prescribing Information Announced For Ortho Evra®_Birth Control Patch Johnson & Johnson 11110/05 
Link: http://www.jnj.com/news/jnj news/20051111 091549.htm 
Ortho Evra FDA Issues Warning Against J&J's Ortha Evra Birth Control Patch kaisemetwork.org. 11111105 
Link: ht!Q:/ /www .kaisemetwork.org/daily reQorts/reQ index.cfm ?hint=2&DR ID=33664 
Ortho Evra New Birth Control Patch Warning Associated Press 11/11105 
(reported by NBC News 
11) 
Link: htto://www.11alive.com/news/healthlhealth article.asQx?storvid=71799 
Ortho Evra Do Not Use the Ortho Evra Birth Control Patch I Public Citizen 111111/05 
Link: htto:/ /www .citizen.org/Qressroom/release.cfm?ID=2081 
Ortho Evra Birth Control Patch Users Warned I CBS News 111111105 
Link: htto://www.cbsnews.com/stories/2005/111111earlyshow/health/health news/main1037611.shtm1 
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Ortho Evra Some Doctors Stop Prescribing Ortho Evra Birth Control Patch After FDA Warning, kaisernetwork.org. 11/22/05 
Wall Street Journal Reports 
Link: http://www.kaisernetwork.org/daily reports/rep index.cfm?hint-2&DR ID-33884 
Ortho Evra Results Of Two Epidemiological Studies Provide Important New Clinical Information Johnson & Johnson 2/16/06 
About The Safety Of OR THO EVRA® 
Link: http://www.jnj .com/news/jnj news/20060217 09333l.htm 
Ortho Evra Birth-Control Patch Users Risk Blood Clots I Washington Post 1 2/16/o6 
Link: http://www.washingtonpost.com/wp-dvn!content/article/2006/02/17 I AR20060217000ll.html 
Ortho Evra Evidence on Ortho Evra Patch Thrombosis Risk Is Contradictory Medpagetoday 2/17/06 
Link: http://www .medpagetoday. com/ProductAlert/Prescriptions/tb/2697 
Ortho Evra Manufacturer Releases Conflicting Studies Concerning Birth Control Patch Users' Risk 
of Developing Blood Clots · 
kaisernetwork.org. 2/17/06 
Link: htto://www.kaisernetwork.org/daily re.Qorts/re.Q index.cfin?DR ID-35473 
Ortho Evra Birth-Control Patch Users Risk Blood Clots Associated Press 2/17/06 
(reported by ABC News) 
Link: htto://abcnews.go.com!Health/wireStoa?id=l630203 
Ortho Evra Birth-control patch linked to blood clots Chicago Tribune 2/17/06 
Link: htto:/ /www.chicagotribune.com/news/nationworld/chi-0602170 115 feb 1 7,1 ,6644359 .stoa?coll=chi -newsnationworld-hed 
Ortho Evra Study: Clot risk doubles with birth control patch Chicago Sun-Times 2/17/06 
Link: htto :/ /www. suntimes.com/ outout/healthl est-nws-.Qatch 1 7 .html 
Ortho Evra Birth Control Patch: How Dangerous Is It? . ABCNaws I 2/17/06 
Link: http://abcnews.go.com/Health/story?id= 1631709&page-l 
Ortho Evra Birth-Control Patch May Boost Risk of Blood Clots I Forbes I 2/17/06 
Link: htt.Q://www .forbes.com/lifestyle/healthlfeeds/hscout/2006/02/17 /hscout531 096.html 
Ortho Evra Study links birth control patch to clots I Newark Star Ledger, NJ 1 2/17/06 
Link: http://www .nj .com/business/ledger/index.ssf? /base/bus_il'l:ess-0/1140241877241540.xml&coll= I 
Ortho Evra FDA: More study needed on birth control patch risk I ABC News 1 2/17/06 
-
Link: http:/ /abcnews. go.com!US/wireStory?id= 1632130 
Ortho Evra J&J unit says mixed blood-clot risk on birth-control· patch I CBS MarketWatch 1 2/17/06 
Link: http://www .marketwatch.com/News/Storv/Storv.aspx?guid-% 7B05699A8E%2D5Ef/6%2D4293%2D926E%2DOE 185DB5B 130 
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- I WebMD Ortho Evra Birth Control Patch May Up Clot Risk 
Link: htt:g://www.webmd.com/content/article/118/113151.htin . 
Ortho Evra Clot risk may rise for women on patch I Houston Chronicle 
Link: ht!J2://www.chron.com/disQ/story.mQllhealth/3668392.htrnl 
Ortho Evra Clot Risk for Birth-Control Patch Is Found to Be Double That of Pill The New York Times 
Link: htto://select.nvtimes.com/gst/abstract.html?res=F50D13F83B5AOC7B8DDDAB0894DE404482 
Ortho Evra Clot of Trouble New York Post 
Link: httQ://www .nYQost.com/news/nationalnews/60 10 1.htrn 
Ortho Evra FDA Official Calls Results of Ortho Evra Birth Control Patch Studies 'Preliminary'; No kaisernetwork.org. 
Regulatory Action Expected 
Link: htto://www.kaisernetwork.org/daily reQorts/reQ index.cfin?DR ID=35514 
Ortho Evra Warning issued for Ortho Evra birth control patch· CNN 
Link: httQ://www.cnn.com/HEALTH/library/DI/0004 7 .htrnl 
- I The State, SC Ortho Evra FDA to look into safety of medicated patches 
Link: htto://www.thestate.com/mld/thestate/news/nation/14035435.htrn 
Ortho Evra FDA Will Review Safety of Medicated Patches, Including Ortho Evra I kaisernetwork.org. 
Link: htto://www.kaisernetwork.org/daily reQorts/reQ index.cfin?DR ID-35820 
Ortho Evra FDA Will Review Safety Of Medicated Patches, Including Ortho EVJ:a Medical News Today 
Link: htto://www.medicalnewstoday.com/medicalnews.QhQ?newsid-39066&nfid=rssfeeds 
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